Vera Therapeutics (VERA) Corporate presentation summary

Company overview and financials

• Founded in 2016 in San Francisco, led by an experienced management team with backgrounds at major biotech firms.

• Raised over $1.8B since IPO in 2021, with $779M in cash and equivalents as of December 2025 and access to an additional $425M in non-dilutive capital.

• Holds exclusive global rights to develop and commercialize atacicept, VT-109, and MAU868.

Atacicept mechanism and clinical profile

• Atacicept is a dual BAFF/APRIL inhibitor, designed as a native human TACI-Fc fusion protein for precision B cell and autoantibody modulation.

• Demonstrates robust efficacy in IgA nephropathy (IgAN), with significant reductions in proteinuria, Gd-IgA1, and hematuria, and stabilization of eGFR.

• Offers at-home, once-weekly administration with high patient retention and a safety profile comparable to placebo, with no serious or opportunistic infections.

Clinical trial results and design

• Phase 3 ORIGIN 3 trial fully enrolled, randomized, placebo-controlled, with primary endpoint of UPCR reduction at 36 weeks and secondary endpoint of eGFR at 104 weeks.

• Interim analysis showed a 46% reduction in UPCR for atacicept vs. 7% for placebo at 36 weeks, with consistent efficacy across subgroups.

• Gd-IgA1 reduction of 68% and 81% hematuria resolution observed; adverse events were generally mild or moderate and balanced between groups.